Table 2.
Necropsy parameters indicating reduced LV remodeling and pulmonary edema in 12/15-LOX and PUFA-fed mice post-MI
| Control Day 0 |
MI Day 1 |
MI Day 5 |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Necropsy Parameters | WT | WT + PUFA | 12/15-LOX−/− | 12/15-LOX−/− + PUFA | WT | WT + PUFA | 12/15-LOX−/− | 12/15-LOX−/− + PUFA | WT | WT + PUFA | 12/15-LOX−/− | 12/15-LOX−/− + PUFA |
| n | 9 | 4 | 5 | 4 | 6 | 5 | 6 | 4 | 9 | 6 | 9 | 7 |
| BW, g | 21 ± 2 | 25 ± 1 | 19 ± 1 | 20 ± 2 | 17 ± 2 | 25 ± 1 | 19 ± 1 | 19 ± 1 | 20 ± 1 | 25 ± 1 | 19 ± 0.5 | 20 ± 1 |
| LV, mg | 65 ± 6 | 79 ± 1 | 64 ± 2 | 66 ± 7 | 75 ± 6 | 83 ± 2 | 73 ± 3 | 70 ± 3 | 96 ± 3* | 98 ± 4* | 88 ± 3*† | 90 ± 4*† |
| LV/BW, mg/g | 3.1 ± 0.04 | 3.1 ± 0.1 | 3.3 ± 0.2 | 3.3 ± 0.1 | 4.4 ± 0.2* | 3.3 ± 0.1 | 3.8 ± 0.1*† | 3.7 ± 0.1*† | 4.9 ± 0.1* | 3.9 ± 0.2*† | 4.8 ± 0.2* | 4.6 ± 0.2* |
| Right ventricle, mg | 17 ± 1 | 16 ± 1 | 15 ± 1 | 19 ± 4 | 16 ± 2 | 16 ± 1 | 17 ± 1 | 19 ± 1 | 18 ± 1 | 20 ± 1 | 16 ± 1 | 23 ± 3 |
| Infarct area, % | ND | ND | ND | ND | 50 ± 2 | 50 ± 2 | 48 ± 2 | 50 ± 1 | 50 ± 1 | 51 ± 1 | 53 ± 1 | 50 ± 1 |
| Lung mass/BW, mg/g | 6 ± 1 | 4 ± 1 | 6 ± 1 | 5 ± 1 | 8 ± 1* | 5 ± 1*† | 8 ± 1* | 7 ± 0.4* | 9 ± 1* | 5 ± 1*† | 9 ± 1* | 7 ± 1*† |
Values are expressed as means ± SE; n indicates sample size. BW, body weight; ND, no infarct in day 0 controls.
*
P < 0.05 vs. day 0 WT controls;
†
P < 0.05 vs. the WT group at the respective day time point.